Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Affiliated Managers (AMG) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Stock is already pricing in higher asset flows.
Apollo (APOL) rated new Buy at Goldman. $54 price target. New enrollment declines should begin to stabilize by the August quarter.Blackstone (BX) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company was also removed from the Conviction List. Valuation call. Carefusion (CFN) downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $30 price target. Columbia Sportswear (COLM) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $70 price target. Sales outlook remains strong. Dr. Pepper Snapple (DPS) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $37 price target. Company is facing higher commodity costs. Education Management (EDMC) downgraded at Goldman to Sell from Neutral, Goldman Sachs said. $18 price target. Company is most exposed to new regulations. Energizer (ENR) downgraded at UBS from Buy to Neutral, UBS said. $76 price target. Focus on Hydro razor could hurt other divisions. Ensco (ESV) upgraded at Morgan Stanley from Underweight to Equal-weight, Morgan Stanley said. $75 price target. Stock is pricing in the recent ban in the Gulf of Mexico. Hershey (HSY) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. Price increases should help drive earnings growth. $59 price target. IBM (IBM) downgraded at Canaccord from Buy to Hold, Canaccord Genuity said. Valuation call, based on a $180 price target. Jack in the Box (JACK) downgraded at Credit Suisse to Underperform from Neutral. Overpaying for a post-refranchising business, Credit Suisse said. Price target lowered by a dollar to $20. Janus (JNS) upgraded at Wells from Market Perform to Outperform. Net outflows should begin to decelerate. Medtronic (MDT) upgraded at Wells from Market Perform to Outperform. Growth is accelerating. Magellan Health (MGLN) rated new Underperform at BofA/Merrill. $50 price target. Organic growth will likely lag peers. Monsanto (MON) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Valuation call, based on a $78 price target.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV